Daxdilimab Biosimilar – Anti-LILRA4 mAb – Research Grade

Daxdilimab Biosimilar: A Novel Anti-LILRA4 Monoclonal Antibody for Therapeutic Targeting

Daxdilimab Biosimilar, also known as Anti-LILRA4 mAb, is a novel monoclonal antibody that has been developed as a biosimilar version of the anti-LILRA4 antibody. It is a research grade antibody that has shown promising results in preclinical studies and is currently being evaluated in clinical trials for its potential therapeutic applications. In this article, we will provide a scientific description of the structure, activity, and potential applications of Daxdilimab Biosimilar.

Structure of Daxdilimab Biosimilar

Daxdilimab Biosimilar is a fully humanized monoclonal antibody that specifically targets the leukocyte immunoglobulin-like receptor A4 (LILRA4). It is composed of two identical heavy chains and two identical light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to its target, while the constant region plays a role in immune effector functions.

The amino acid sequence of Daxdilimab Biosimilar has been engineered to be highly similar to the reference anti-LILRA4 antibody, ensuring its biosimilarity. It has a molecular weight of approximately 150 kDa and a half-life of approximately 21 days in humans.

Mechanism of Action

LILRA4 is a cell surface receptor that is expressed on various immune cells, including monocytes, macrophages, and dendritic cells. It is known to play a role in regulating immune responses and has been implicated in the pathogenesis of several autoimmune and inflammatory diseases.

Daxdilimab Biosimilar binds to LILRA4 with high affinity, thereby blocking its interaction with its ligands and inhibiting downstream signaling pathways. This leads to a decrease in the production of pro-inflammatory cytokines and an increase in the production of anti-inflammatory cytokines, resulting in a modulation of the immune response.

Potential Applications

Daxdilimab Biosimilar has shown promising results in preclinical studies for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. It has also been evaluated in animal models of cancer, where it has demonstrated potential as an immunotherapeutic agent by enhancing anti-tumor immune responses.

Currently, Daxdilimab Biosimilar is being evaluated in clinical trials for the treatment of rheumatoid arthritis and psoriasis. These trials aim to assess the safety, efficacy, and pharmacokinetics of the antibody in human subjects, with the ultimate goal of obtaining regulatory approval for its use in these indications.

Conclusion

Daxdilimab Biosimilar is a novel monoclonal antibody that specifically targets LILRA4 and has shown promising results in preclinical studies for the treatment of autoimmune and inflammatory diseases. Its biosimilarity to the reference anti-LILRA4 antibody and its mechanism of action make it a potential therapeutic option for these diseases. Ongoing clinical trials will provide further insights into the safety and efficacy of Daxdilimab Biosimilar and its potential to improve patient outcomes.

Keywords: Daxdilimab Biosimilar, Anti-LILRA4 mAb, monoclonal antibody, biosimilar, leukocyte immunoglobulin-like receptor A4, LILRA4, autoimmune diseases, inflammatory diseases, immunotherapy